24/7 Customer Support

Osimertinib Drugs Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2027

Global Osimertinib Drugs Market- (By Type- 40 mg and 80 mg; By Application- Hospitals and Drug Stores; and By Region) - Industry Dynamics, Market Size and Opportunity Forecast, 2027

  • Published On: 09-Jun-2022  |   Format: pdfpowerpointexcel  |  Report ID: AA0622264
    Delivery: 2 to 4 Hours


Osimertinib drugs is used for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Tagrisso, AZD9291, mereletinib, osimertinib mesilate and osimertinib mesylate are the other names for osimertinib drug.

The global osimertinib drugs market is studied from 2016-2027. 

The growth rate of the global osimertinib drugs market is 16.1%, with an estimated value of US$ 11,892.8 Million by 2027. 

North America held the major share in terms of revenue in the global osimertinib drugs market in 2021. 

Factors such as surging demand for effective medication for the management of lung cancer and tagrisso an effective alternative for the treatment of NSCLC with mutation drives the growth in the global osimertinib drugs market.

Availability of counterfeit products in the market is a restraining factor which inhibits the growth of the market during the forecast period.

Type, application and region are the different segments of the global osimertinib drugs market. 

Major market players are investing highly in research and development in order to develop an effective medication, thus providing a lucrative growth opportunity for the market.

The hospitals segment holds the largest market share in 2021 in the global osimertinib drugs market.

China is expected to project the highest CAGR during the forecast period in the Asia Pacific osimertinib drugs market. 

The key players operating in the market include AstraZeneca, Incepta Pharmaceuticals Limited, Everest Pharmaceuticals, Beacon Pharma and Drug International among others.